568 related articles for article (PubMed ID: 22356303)
41. Development and characterization of cellulose-polymethacrylate mucoadhesive film for buccal delivery of carvedilol.
Meher JG; Tarai M; Yadav NP; Patnaik A; Mishra P; Yadav KS
Carbohydr Polym; 2013 Jul; 96(1):172-80. PubMed ID: 23688467
[TBL] [Abstract][Full Text] [Related]
42. In vitro and in vivo assessment of matrix type transdermal therapeutic system of labetalol hydrochloride.
Mittal A; Parmar S; Singh B
Curr Drug Deliv; 2009 Oct; 6(5):511-9. PubMed ID: 19863491
[TBL] [Abstract][Full Text] [Related]
43. Fabrication and characterization of matrix type transdermal patches loaded with tizanidine hydrochloride: potential sustained release delivery system.
Shahid N; Siddique MI; Razzaq Z; Katas H; Waqas MK; Rahman KU
Drug Dev Ind Pharm; 2018 Dec; 44(12):2061-2070. PubMed ID: 30081679
[TBL] [Abstract][Full Text] [Related]
44. Comparison of the pharmacokinetic properties of bisoprolol and carvedilol in healthy dogs.
Beddies G; Fox PR; Papich MD; Kanikanti VR; Krebber R; Keene BW
Am J Vet Res; 2008 Dec; 69(12):1659-63. PubMed ID: 19046015
[TBL] [Abstract][Full Text] [Related]
45. Pharmacokinetic and pharmacodynamic properties of carvedilol in fructose hypertensive rats.
Bertera F; Di Verniero CA; Mayer MA; Chiappetta D; Buontempo F; Polizio AH; Taira CA; Höcht C
Xenobiotica; 2012 Feb; 42(2):206-19. PubMed ID: 21892881
[TBL] [Abstract][Full Text] [Related]
46. Analysis of carvedilol enantiomers in human plasma using chiral stationary phase column and liquid chromatography with tandem mass spectrometry.
Poggi JC; Da Silva FG; Coelho EB; Marques MP; Bertucci C; Lanchote VL
Chirality; 2012 Mar; 24(3):209-14. PubMed ID: 22271587
[TBL] [Abstract][Full Text] [Related]
47. Enantioselective pharmacokinetic-pharmacodynamic modelling of carvedilol in a N-nitro-l-arginine methyl ester rat model of secondary hypertension.
Di Verniero CA; Bertera F; Buontempo F; Bernabeu E; Chiappetta D; Mayer MA; Bramuglia GF; Taira CA; Höcht C
J Pharm Pharmacol; 2010 Jul; 62(7):890-900. PubMed ID: 20636877
[TBL] [Abstract][Full Text] [Related]
48. Enhanced transdermal delivery of an anti-hypertensive agent via nanoethosomes: statistical optimization, characterization and pharmacokinetic assessment.
Ahad A; Aqil M; Kohli K; Sultana Y; Mujeeb M
Int J Pharm; 2013 Feb; 443(1-2):26-38. PubMed ID: 23313344
[TBL] [Abstract][Full Text] [Related]
49. In vivo evaluation of limonene-based transdermal therapeutic system of nicorandil in healthy human volunteers.
Krishnaiah YS; Chandrasekhar DV; Rama B; Jayaram B; Satyanarayana V; Al-Saidan SM
Skin Pharmacol Physiol; 2005; 18(6):263-72. PubMed ID: 16113596
[TBL] [Abstract][Full Text] [Related]
50. Development and evaluation of matrix type transdermal patch of ethinylestradiol and medroxyprogesterone acetate for anti-implantation activity in female Wistar rats.
Agrawal SS; Pruthi JK
Contraception; 2011 Nov; 84(5):533-8. PubMed ID: 22018130
[TBL] [Abstract][Full Text] [Related]
51. Solubility enhancement and physicochemical characterization of carvedilol solid dispersion with Gelucire 50/13.
Potluri RH; Bandari S; Jukanti R; Veerareddy PR
Arch Pharm Res; 2011 Jan; 34(1):51-7. PubMed ID: 21468915
[TBL] [Abstract][Full Text] [Related]
52. Design, development, physicochemical, in vitro and in vivo evaluation of monolithic matrix type transdermal patches containing nitrendipine.
Mittal A; Sara US; Ali A; Mohammed A
Pharm Dev Technol; 2009; 14(4):422-34. PubMed ID: 19630699
[TBL] [Abstract][Full Text] [Related]
53. In vitro and in vivo transdermal iontophoretic delivery of naloxone, an opioid antagonist.
Yamamoto R; Takasuga S; Yoshida Y; Mafune S; Kominami K; Sutoh C; Kato Y; Yamauchi M; Ito M; Kanamura K; Kinoshita M
Int J Pharm; 2012 Jan; 422(1-2):132-8. PubMed ID: 22108639
[TBL] [Abstract][Full Text] [Related]
54. Nanosuspension based in situ gelling nasal spray of carvedilol: development, in vitro and in vivo characterization.
Saindane NS; Pagar KP; Vavia PR
AAPS PharmSciTech; 2013 Mar; 14(1):189-99. PubMed ID: 23255198
[TBL] [Abstract][Full Text] [Related]
55. Preparation, in-vitro and in-vivo characterization of transdermal patch containing glibenclamide and atenolol: a combinational approach.
Anitha P; Ramkanth S; Saleem MT; Umasankari K; Reddy BP; Chetty M
Pak J Pharm Sci; 2011 Apr; 24(2):155-63. PubMed ID: 21454164
[TBL] [Abstract][Full Text] [Related]
56. Studies on formulation development of mouth dissolving tablets of Carvedilol.
Pokharkar V; Dhar S; Mandpe L
Hindustan Antibiot Bull; 2007 Feb-2008 Nov; 49-50(1-4):21-8. PubMed ID: 19957540
[TBL] [Abstract][Full Text] [Related]
57. PREPARATION, IN VITRO AND IN VIVO CHARACTERIZATION OF HYDROPHOBIC PATCHES OF A HIGHLY WATER SOLUBLE DRUG FOR PROLONGED PLASMA HALF LIFE: EFFECT OF PERMEATION ENHANCERS.
Yaqoob A; Ahmad M; Mahmood A; Sarfraz RM
Acta Pol Pharm; 2016 Nov; 73(6):1639-1648. PubMed ID: 29634120
[TBL] [Abstract][Full Text] [Related]
58. Natural oils as skin permeation enhancers for transdermal delivery of olanzapine: in vitro and in vivo evaluation.
Aggarwal G; Dhawan S; HariKumar SL
Curr Drug Deliv; 2012 Mar; 9(2):172-81. PubMed ID: 22023211
[TBL] [Abstract][Full Text] [Related]
59. Synthesis and evaluation of esmolol prodrugs for transdermal delivery.
Bijaya G; Kaushal D; Sonal D; Pallavi K
Drug Deliv; 2010; 17(7):532-40. PubMed ID: 20553111
[TBL] [Abstract][Full Text] [Related]
60. Investigations of a novel self-emulsifying osmotic pump tablet containing carvedilol.
Wei L; Li J; Guo L; Nie S; Pan W; Sun P; Liu H
Drug Dev Ind Pharm; 2007 Sep; 33(9):990-8. PubMed ID: 17891586
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
